Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 6:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 36 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo 70 mg/mL Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia

NCT01644474
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Alirocumab, Ezetimibe, Placebo (for Alirocumab), Placebo (for Ezetimibe)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Overland Park, Kansas • Cincinnati, Ohio • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 5, 2015 · Synced Sep 17, 2026, 6:24 PM EDT
Completed Phase 3 Interventional Results available

Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)

NCT01730053
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Alirocumab, Rosuvastatin, Ezetimibe, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
54
States / cities
Chandler, Arizona • Tucson, Arizona • Anaheim, California + 51 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2020 · Synced Sep 17, 2026, 6:24 PM EDT
Completed Phase 2 Interventional Results available

Effects and Safety of OPK-88003 Dose Escalation in Type 2 Diabetes Subjects

NCT03406377
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
OPK-88003, Placebo
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Huntington Park, California • Los Angeles, California • Hialeah, Florida
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Sep 17, 2026, 6:24 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Effects of Red Beetroot Juice on High-Fat Meal-Induced Endothelial Dysfunction and Cardiometabolic Disturbances

NCT02949115
View directory record Official record
Conditions
Overweight, Obesity, Aging, Menopause
Interventions
70 mL red beetroot juice, 70 mL red beetroot juice without nitrate, 70 mL placebo drink plus potassium nitrate, 70 mL placebo drink
Dietary Supplement
Lead sponsor
Colorado State University
Other
Eligibility
40 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 12, 2018 · Synced Sep 17, 2026, 6:24 PM EDT
Completed Phase 3 Interventional Results available

Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)

NCT01709513
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Atorvastatin, Ezetimibe, Alirocumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
41
States / cities
Anaheim, California • Beverly Hills, California • Mission Viejo, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2020 · Synced Sep 17, 2026, 6:24 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Adjuvant Nitrate to Boost Exercise-induced Health Benefits in Older Adults

NCT07572266
View directory record Official record
Conditions
Aging, Aging Well, Healthy Aging
Interventions
Nitrate enriched beetroot juice, Nitrate depleted beetroot juice, 12 week of combined exercise training
Dietary Supplement · Other
Lead sponsor
Florida Institute for Human and Machine Cognition
Other
Eligibility
60 Years and older
Enrollment
226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Pensacola, Florida
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 17, 2026, 6:24 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention

NCT03238781
View directory record Official record
Conditions
Chronic Migraine or Episodic Migraine
Interventions
Placebo, AMG 301
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 60 Years
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
21
States / cities
Long Beach, California • Santa Monica, California • Boulder, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2020 · Synced Sep 17, 2026, 6:24 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety and Tolerability of a Recombinant Herpes Zoster Vaccine

NCT05750017
View directory record Official record
Conditions
Herpes Zoster, Vaccine-Preventable Diseases
Interventions
Low Dose Recombinant Herpes Zoster Vaccine (LZ901), High Dose Recombinant Herpes Zoster Vaccine (LZ901), Placebo
Biological · Drug
Lead sponsor
Beijing Luzhu Biotechnology Co., Ltd.
Other
Eligibility
50 Years to 70 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 26, 2023 · Synced Sep 17, 2026, 6:24 PM EDT
Completed Phase 3 Interventional Results available

Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)

NCT01730040
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Alirocumab, Atorvastatin, Ezetimibe, Rosuvastatin, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
56
States / cities
Mobile, Alabama • Chandler, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2015 · Synced Sep 17, 2026, 6:24 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Acute Graft-Versus-Host Disease (GVHD) in Patients Undergoing Allogeneic Stem-Cell Transplantation

NCT02737306
View directory record Official record
Conditions
Graft Vs Host Disease
Interventions
PRO 140, Placebo
Drug
Lead sponsor
CytoDyn, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
8
States / cities
Miami, Florida • Maywood, Illinois • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Sep 17, 2026, 6:24 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Randomized Controlled Trial of Silymarin in Asthma

NCT01049178
View directory record Official record
Conditions
Atopic Asthma
Interventions
Oral Silymarin, Oral Silymarin, maintenance dose, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 23, 2014 · Synced Sep 17, 2026, 6:24 PM EDT
Completed Phase 4 Interventional

Rapydan Topical Anaesthesia for Arterial Cannulation

NCT01494311
View directory record Official record
Conditions
Arterial Catheterization
Interventions
Lidocaine/tetracaine patch, Placebo Patch, Subcutaneous injection of 0.5 ml Lidocain 1%, Subcutaneous injection of saline
Drug
Lead sponsor
Medical University of Vienna
Other
Eligibility
18 Years to 90 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 17, 2013 · Synced Sep 17, 2026, 6:24 PM EDT
Completed Phase 3 Interventional Results available

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

NCT00000620
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension, Diabetes Mellitus, Type 2, Diabetes Mellitus, Coronary Disease
Interventions
Anti-hyperglycemic Agents, Anti-hypertensive Agents, Blinded fenofibrate or placebo plus simvastatin
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
40 Years to 79 Years
Enrollment
10,251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
6
States / cities
Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced Sep 17, 2026, 6:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Phytochemicals From Theobroma Cacao on Mental Energy

NCT01651793
View directory record Official record
Conditions
Mental Fatigue
Interventions
Caffeinated cocoa, Cocoa, Caffeine, Placebo
Other
Lead sponsor
University of Georgia
Other
Eligibility
18 Years to 34 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Athens, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 24, 2018 · Synced Sep 17, 2026, 6:24 PM EDT
Completed Phase 2 Interventional Results available

A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.

NCT03751657
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin icodec, Placebo (insulin 287), Metformin, Dipeptidyl peptidase-4 inhibitors, Insulin glargine, Placebo (insulin glargine)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
14
States / cities
Lancaster, California • Ventura, California • Walnut Creek, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Sep 17, 2026, 6:24 PM EDT
Completed Phase 3 Interventional Results available

Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy

NCT02851797
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
givinostat, placebo
Drug
Lead sponsor
Italfarmaco
Industry
Eligibility
6 Years to 17 Years · Male only
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
13
States / cities
Davis, California • San Diego, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Sep 17, 2026, 6:24 PM EDT
Completed Phase 3 Interventional Results available

Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma

NCT02807636
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
Atezolizumab, Carboplatin, Gemcitabine, Placebo, Cisplatin
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
18
States / cities
Rogers, Arkansas • San Luis Obispo, California • New Haven, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Sep 17, 2026, 6:24 PM EDT
Completed Phase 2 Interventional Results available

Safety and Effectiveness of Alendronate for Bone Mineral Density in HIV-infected Children and Adolescents

NCT00921557
View directory record Official record
Conditions
HIV Infection
Interventions
Alendronate, Placebo, Calcium carbonate/vitamin D
Drug · Dietary Supplement
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
11 Years to 24 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
7
States / cities
Los Angeles, California • Miami, Florida • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Sep 17, 2026, 6:24 PM EDT
Terminated Phase 2 Interventional Results available

Erenumab-aooe for Temporomandibular Disorders Management: TMD Cgrp Antibody RElief (TMD CARE)

NCT05162027
View directory record Official record
Conditions
Temporomandibular Disorders
Interventions
Erenumab-Aooe 70 MG in 1 mL Prefilled Syringe, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Sep 17, 2026, 6:24 PM EDT
Recruiting Phase 2 Interventional

Treatment of Acute PTH With a CGRP Receptor mAb in Military Service Members and Civilians With mTBI

NCT05049057
View directory record Official record
Conditions
Posttraumatic Headache, Mild Traumatic Brain Injury
Interventions
Erenumab 140 Mg/mL Subcutaneous Solution, Placebo
Drug
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Fort Bragg, North Carolina • Pittsburgh, Pennsylvania • El Paso, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Sep 17, 2026, 6:24 PM EDT
Completed Phase 3 Interventional Results available

A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis

NCT02016716
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
Romosozumab 90 mg/mL, Placebo 90 mg/mL, Romosozumab 70 mg/mL, Placebo 70 mg/mL
Drug
Lead sponsor
Amgen
Industry
Eligibility
55 Years to 90 Years · Female only
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Gainesville, Georgia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Sep 17, 2026, 6:24 PM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy

NCT01405508
View directory record Official record
Conditions
Epilepsy
Interventions
Brivaracetam tablets, Brivaracetam bolus, Brivaracetam infusion, Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
16 Years to 70 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
8
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Lexington, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Sep 17, 2026, 6:24 PM EDT
Recruiting Phase 4 Interventional

Colchicine's Effect on Inflammatory Markers

NCT07287345
View directory record Official record
Conditions
Colchicine, Inflammation in Cardiac Surgery, Post Operative Atrial Fibrillation, Inflammatory Markers, Colchicine Adverse Reaction
Interventions
Colchicine (Colcrys®), Placebo
Drug
Lead sponsor
Ayesha Ather
Other
Eligibility
18 Years to 99 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 17, 2026, 6:24 PM EDT
Recruiting Phase 1 Interventional

Effect of Insulin Lowering on Lipogenesis

NCT07403604
View directory record Official record
Conditions
Hyperinsulinemia, Insulin Resistance, Non-Alcoholic Fatty Liver Disease, Prediabetic State, Obesity
Interventions
Placebo, Diazoxide Oral Suspension, 2 mg per kg per dose, Deuterated water (2H2O/D2O), 70%, Insulin Suppression Test (IST)
Drug · Diagnostic Test
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 17, 2026, 6:24 PM EDT